Cyclooxygenase in the treatment of glioma: Its complex role in signal transduction

Cancer Control

Volumn 11, Issue 3, 2004, Pages 152-164

  New, Pamela ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ALPHA TOCOPHEROL; ANGIOGENESIS INHIBITOR; APC PROTEIN; CELECOXIB; COLCHICINE; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DEXAMETHASONE; DOCETAXEL; FLUOROURACIL; FOLINIC ACID; FUREGRELATE; IBUPROFEN; IMATINIB; INDOMETACIN; KETOPROFEN; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PACLITAXEL; PIROXICAM; PROSTAGLANDIN SYNTHASE; RETINOID; ROFECOXIB; SALICYLATE SODIUM; SALICYLIC ACID; SULINDAC SULFONE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTHRALGIA; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL TRIAL; DRUG BINDING SITE; DRUG EFFECT; DRUG MEGADOSE; DRUG POTENTIATION; DRUG PROTEIN BINDING; ENZYME INHIBITION; ENZYME MECHANISM; ENZYME STRUCTURE; GASTROINTESTINAL HEMORRHAGE; GLIOMA; HUMAN; IN VITRO STUDY; IN VIVO STUDY; MYALGIA; NONHUMAN; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; TUMOR GROWTH;

EID: 2942534202     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480401100303     Document Type: Review

References (119)

1. Hinz B, Brune K. Cyclooxygenase-2: 10 years later. Pharmacol Exp Ther. 2002;300:367-375.
2. Kurzel F, Hagel CH, Zapf S, et al. Cyclo-oxygenase inhibitors and thromboxane synthase inhibitors differentially regulate migration arrest, growth inhibition and apoptosis in human glioma cells. Acta Neurochir (Wien). 2002;144:71-87.
3. Thun MJ, Henley SJ, Patrono C. Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst. 2002;94:252-266.
4. Inoue H, Kosaka T, Miyata A, et al. Structure and expression of the human prostaglandin endoperoxide synthase 2 gene. Adv Prostaglandin Thromboxane Leukot Res. 1995;23:109-111.
5. Cannon GW. Cyclooxygenase-2 selective inhibitors. Drugs Today (Barc). 1999;35:487-496. Erratum in: Drugs Today (Barc). 2003; 35:980 and 2003;35:739.
6. Cannon GW. Cyclooxygenase-2 selective inhibitors. Drugs Today (Barc). 1999;35:487-496. Erratum in: Drugs Today (Barc). 2003; 35:980 and 2003;35:739.
7. Cannon GW. Cyclooxygenase-2 selective inhibitors. Drugs Today (Barc). 1999;35:487-496. Erratum in: Drugs Today (Barc). 2003; 35:980 and 2003;35:739.
8. Ma N, Szabolcs MJ, Sun J, et al. The effect of selective inhibition of cyclooxygenase (COX)-2 on acute cardiac allograft rejection. Transplantation. 2002;74:1528-1534.
9. Reid G, Wielinga P, Zelcer N, et al. The human multidrug resistance protein MRP4 functions as a prostaglandin efflux transporter and is inhibited by nonsteroidal anti-inflammatory drugs. Proc Natl Acad Sci U S A. 2003;100:9244-9249.
10. Cannon GW, Breedveld FC. Efficacy of cyclooxygenase-2 specific inhibitors. Am J Med. 2001;110(suppl 3A):6S-12S.
11. Deininger MH, Schluesener HJ. Cyclooxygenase-1 and -2 are differentially localized to microglia and endothelium in rat EAE and glioma. J Neuroimmunol. 1999;95:202-208.
12. Gumgumji AA, Dawood T, Parvez T. Role of COX-2 specific inhibitors in oncogenesis. J Coll Physicians Surg Pak. 2003;13: 361-365.
13. King JG Jr, Khalili K. Inhibition of human brain tumor cell growth by the anti-inflammatory drugs flurbiprofen. Oncogene. 2001;20: 6864-6870.
14. Bennett A, Del Tacca M. Proceedings: prostaglandins in human colonic carcinoma. Gut. 1975;16:409.
15. Pollard M, Zedeck MS. Induction of colon tumors in 1,2-dimethylhydra- zine-resistant Lobund Wistar rats by methylazoxymethanol acetate. J Natl Cancer Inst. 1978;61:493-494.
16. Kudo T, Narisawa T, Abo S. Antitumor activity of indomethacin on methylazoxymethanol-induced large bowel tumors in rats. Gann. 1980;71:260-264.
17. Narisawa T, Sato M, Tani M, et al. Inhibition of development of methylnitrosourea-induced rat colon tumors by indomethacin treatment. Cancer Res. 1981;41:1954-1957.
18. Kawamori T, Rao CV, Seibert K, et al. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 1998;58:409-412.
19. Evans JF. Rofecoxib (Vioxx), a specific cyclooxygenase-2 inhibitor, is chemopreventive in a mouse model of colon cancer. Am J Clin Oncol. 2003;26:S62-S65.
20. Chau I, Cunningham D. Cyclooxygenase inhibition in cancer: a blind alley or a new therapeutic reality. N Engl J Med. 2002;346: 1085-1087.
21. Tonelli F, Valanzano R. Sulindac in familial adenomatous polyposis. Lancet. 1993;342:1120.
22. Garcia Rodriguez LA, Huerta-Alaverez C. Reduced incidence of colorectal adenoma among long-term users of nonsteroidal anti inflammatory drugs: a pooled analysis of published studies and a new population-based study. Epidemiology. 2000;11:376-381.
23. Sandler RS, Galanko JC, Murray SC, et al. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology. 1998;114:441-447.
24. Breuer-Katschinski B, Nemes K, Rump B, et al. Long-term use of nonsteroidal anti-inflammatory drugs and the risk of colorectal adenomas: the Colorectal Adenoma Study Group. Digestion. 2000;61:129-134.
25. Paganini-Hill A, Chao A, Ross RK, et al. Aspirin use and chronic diseases: a cohort study of the elderly. BMJ. 1989;299:1247-1250.
26. Bedi A, Pasricha PJ, Akhtar AJ, et al. Inhibition of apoptosis during development of colorectal cancer. Cancer Res. 1995;55:1811-1816.
27. He TC, Sparks AB, Rago C, et al. Identification of c-MYC as a target of the APC pathway. Science. 1998;281:1509-1512.
28. Kopp E, Ghosh S. Inhibition of NF-kappa B by sodium salicylate and aspirin. Science. 1994;265:956-958.
29. Yamamoto Y, Yin MJ, Lin KM, et al. Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999;274:27307-27314.
30. Schwenger P, Bellosta P, Vietor I, et al. Sodium salicylate induces apoptosis via P38 mitogen-activated protein kinase by but inhibits tumor necrosis factor-induced c-Jun N-terminal kinase/stress-activated protein kinase activation. Proc Natl Acad Sci U S A. 1997;94:2869-2873.
31. Schwenger P, Alpert D, Skolnik EY, et al. Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Moll Cell Biol. 1998;18:78-84.
32. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716. Erratum in: Cell. 1998;94(2):following 271.
33. Tsujii M, Kawano S, Tsuji S, et al. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell. 1998;93:705-716. Erratum in: Cell. 1998;94(2):following 271.
34. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat Med. 1999;5:1418-1423.
35. Wu AW, Gu J, Ji JF, et al. Role of COX-2 in carcinogenesis of colorectal cancer and its relationship with tumor biological characteristics and patients' prognosis. World J Gastroenterol. 2003;9: 1990-1994.
36. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60:1306-1311.
37. Leahy KM, Omberg RL, Wang Y, et al. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002;62:625-631.
38. Yu JL, Rak JW, Coomber BL, et al. Effect of p53 status on tumor response to antiangiogenic therapy. Science. 2002;295:1526-1528.
39. Subbaramaiah K, Lin DT, Hart JC, et al. Peroxisome proliferator-activated receptor gamma ligands suppress the transcriptional activation of cyclooxygenase-2: evidence for involvement of activator protein-1 and CREB-binding protein/p300. J Biol Chem. 2001;276: 12440-12448.
40. Ramer R, Weinzierl U, Schwind B, et al. Ceramide is involved in r(+)-methanandamide-induced cyclooxygenase-2 expression in human neuroglioma cells. Mol Pharmacol. 2003;64:1189-1198.
41. Subbaramaiah K, Chung WJ, Dannenberg AJ. Ceramide regulates the transcription of cyclooxygenase-2: evidence for involvement of extracellular signal-regulated kinase/c-Jun N-terminal kinase and p38 mitogen-activated protein kinase pathways. J Biol Chem. 1998;273:32943-32949.
42. Dommels YE, Haring MM, Keestra NG, et al. The role of cyclooxygenase in n-6 and n-3 polyunsaturated fatty acid mediated effects on cell proliferation, PGE(2) synthesis and cytotoxicity in human colorectal carcinoma cell lines. Carcinogenesis. 2003;24:385-392.
43. Levitt RJ, Pollak M. Insulin-like growth factor-I antagonizes the antiproliferative effects of cyclooxygenase-2 inhibitors on BxPC-3 pancreatic cancer cells. Cancer Res. 2002;62:7372-7376.
44. Eibl G, Reber HA, Wente MN, et al. The selective cyclooxygenase-2 inhibitor nimesulide induces apoptosis in pancreatic cancer cells independent of COX-2. Pancreas. 2003;26:33-41.
45. Li M, Lotan R, Levin B, et al. Aspirin induction of apoptosis in esophageal cancer: a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev. 2000;9:545-549.
46. Shi H, Xu JM, Hu NZ, et al. Prognostic significance of expression of cyclooxygenase-2 and vascular endothelial growth factor in human gastric carcinoma. World J Gastroenterol. 2003;9:1421-1426.
47. Brecher AR. The role of cyclooxygenase-2 in the pathogenesis of skin cancer. J Drugs Dermatol. 2002;1:44-47.
48. Tripp CS, Bloome EA, Chinn KS, et al. Epidermal COX-2 induction following ultraviolet irradiation: suggested mechanism for the role of COX-2 inhibition in photoprotection. J Invest Dermatol. 2003;121:853-861.
49. Marks F, Furstenberger G, Neufang G, et al. Mouse skin as a model for cancer chemoprevention by nonsteroidal anti-inflammatory drugs. Recent Results Cancer Res. 2003;163:46-57; discussion 264-266.
50. Denkert C, Kobel M, Berger S, et al. Expression of cyclooxygenase 2 in human malignant melanoma. Cancer Res. 2001;61:303-308.
51. Kirschenbaum A, Klausner AP, Lee R, et al. Expression of cyclooxygenase-1 and cyclooxygenase-2 in the human prostate. Urology. 2000;56:671-676.
52. Kirschenbaum A, Liu X, Yao S, et al. The role of cyclooxygenase-2 in prostate cancer. Urology. 2001;58(2 suppl 1):127-131.
53. Liu XH, Yao S, Kirschenbaum A, et al. NS398, a selective cyclooxygenase-2 inhibitor, induces apoptosis and down-regulates bcl-2 expression in LNCaP cells. Cancer Res. 1998;58:4245-4249.
54. Hsu AL, Ching TT, Wang DS, et al. The cyclooxygenase-2 inhibitor celecoxib induces apoptosis by blocking Akt activation in human prostate cancer cells independently of Bcl-2. J Biol Chem. 2000;275:11397-11403.
55. Liu XH, Kirschenbaum A, Yao S, et al. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J Urol. 2000;164(3 pt 1):820-825.
56. Liu XH, Kirschenbaum A, Lu M, et al. Prostaglandin E2 induces hypoxia-inducible factor-1alpha stabilization and nuclear localization in human prostate cancer cell line. J Biol Chem. 2002;277:50081-50086.
57. Palayoor ST, Tofilon PJ, Coleman CN. Ibuprofen-mediated reduction of hypoxia-inducible factors HIF 1alpha and HIF-2alpha in prostate cancer cells. Clin Cancer Res. 2003;9:3150-3157.
58. Fujita H, Koshida K, Keller ET, et al. Cyclooxygenase-2 promotes prostate cancer progression. Prostate. 2002;53:232-240.
59. Ristimäki A, Nieminen O, Saukkonen K, et al. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. Am J Pathol. 2001;158:849-853.
60. Wülfing C, Eltze E, von Struensee D, et al. Cyclooxygenase-2 expression in bladder cancer: correlation with poor outcome after chemotherapy. Eur Urol. 2004;45:46-52.
61. Pruthi RS, Derksen E, Gaston K. Cyclooxygenase-2 as a potential target in the prevention and treatment of genitourinary tumors: a review. J Urol. 2003;169:2352-2359.
62. Gridelli C, Maione P, Airoma G, et al. Selective cyclooxygenase-2 inhibitors and non-small cell lung cancer. Curr Med Chem. 2002;9:1851-1858.
63. Sanchez-Alcazar JA, Bradbury DA, Pang L, et al. Cyclooxygenase (COX) inhibitors induce apoptosis in non-small cell lung cancer through cyclooxygenase independent pathways. Lung Cancer. 2003;40:33-44.
64. Denkert C, Köbel M, Pest S, et al, Expression of cyclooxygenase 2 is an independent prognostic factor in human ovarian carcinoma. Am J Pathol. 2002;160:893-903.
65. Sales KJ, Katz AA, Howard B, et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors and angiogenic factors of cyclooxygenase-1. Cancer Res. 2002;62:424-432. Erratum in: Cancer Res. 2002;62(5):1579.
66. Sales KJ, Katz AA, Howard B, et al. Cyclooxygenase-1 is up-regulated in cervical carcinomas: autocrine/paracrine regulation of cyclooxygenase-2, prostaglandin e receptors and angiogenic factors of cyclooxygenase-1. Cancer Res. 2002;62:424-432. Erratum in: Cancer Res. 2002;62(5):1579.
67. Phipps RP, Ryan E, Bernstein SH. Inhibition of cyclooxygenase-2: a new targeted therapy for B-cell lymphoma? Leuk Res. 2004;28: 109-111.
68. Denkert C, Winzer KJ, Muller BM, et al. Elevated expression of cyclooxygenase-2 is a negative prognostic factor for disease free survival and overall survival in patients with breast carcinoma. Cancer. 2003;97:2978-2987.
69. Davies G, Salter J, Hills M, et al. Correlation between cyclooxygenase-2 expression and angiogenesis in human breast cancer. Clin Cancer Res. 2003;9:2651-2656.
70. McCormick DL, Moon RC. Inhibition of mammary carcinogenesis by flurbiprofen, a non-steroidal anti-inflammatory agent. Br J Cancer. 1983;48:859-861.
71. Chang SH, Liu CH, Conway R, et al. Role of prostaglandin E2-dependent angiogenic switch in cyclooxygenase 2-induced breast cancer progression. Proc Natl Acad Sci U S A. 2004;101:591-596.
72. Ristimäki A, Sivula A, Lundin J, et al. Prognostic significance of elevated cyclooxygenase-2 expression in breast cancer. Cancer Res. 2002;62:632-635.
73. Wilson DE, Anderson KM, Seed TM. Ultrastructural evidence for differentiation in a human glioblastoma cell line treated with inhibitors of eicosanoid metabolism. Neurosurgery. 1990;27:523-531.
74. Joki T, Heese O, Nikas DC, et al. Expression of cyclooxygenase-2 (COX-2) in human glioma and in vitro inhibition by a specific COX-2 inhibitor, NS-398. Cancer Res. 2000;60:4926-4931.
75. Prayson RA, Castilla EA, Vogelbaum MA, et al. Cyclooxygenase-2 (COX-2) expression by immunohistochemistry in glioblastoma multiforme. Ann Diagn Pathol. 2002;6:148-153.
76. Shono T, Tofilon PJ, Bruner JM, et al. Cyclooxygenase-2 expression in human gliomas: prognostic significance and molecular correlations. Cancer Res. 2001;61:4375-4381.
77. Badie B, Schartner JM, Hagar AR, et al. Microglia cyclooxygenase-2 activity in experimental gliomas: possible role in cerebral edema formation. Clin Cancer Res. 2003;9:872-877.
78. Deininger MH, Meyermann R, Trautmann K, et al. Cyclooxygenase (COX)-1 expressing macrophages/microglial cells and COX-2 expressing astrocytes accumulate during oligodendroglioma progression. Brain Res. 2000;885:111-116.
79. Hernandez M, Bayon Y, Sanchez Crespo M, et al. Signaling mechanisms involved in the activation of arachidonic acid metabolism in human astrocytoma cells by tumor necrosis factor-alpha: phosphorylation of cytosolic phospholipase A2 and transactivation of cyclooxygenase-2. J Neurochem. 1999;73:1641-1649.
80. Hernandez M, de Arriba AF, Merlos M, et al. Effect of 4-trifluoromethyl derivatives of salicylate on nuclear factor kappaB-dependent transcription in human astrocytoma cells. Br J Pharmacol. 2001;132:547-555.
81. Moynagh PN, Williams DC, O'Neill LA. Activation of NF-kappa B and induction of vascular cell adhesion molecule-1 and intracellular adhesion molecule-1 expression in human glial cells by IL-1: modulation by antioxidants. J Immunol. 1994;153:2681-2690.
82. Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of I(kappa)B kinase-beta. Nature. 1998;396:77-80.
83. Bourke E, Kennedy EJ, Moynagh PN. Loss of Ikappa B-beta is associated with prolonged NF-kappa B activity in human glial cells. J Biol Chem. 2000;275:39996-40002.
84. Meade EA, McIntyre TM, Zimmerman GA, et al. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J Biol Chem. 1999;274:8328-8334.
85. Paik JH, Ju JH, Lee JY, et al. Two opposing effects of non-steroidal anti-inflammatory drugs on the expression of the inducible cyclooxygenase: mediation through different signaling pathways. J Biol Chem. 2000;275:28173-28179.
86. Gati I, Bergstrom M, Westerberg G, et al. Effects of prostaglandin and leukotriene inhibitors on the growth of human glioma spheroids. Eur J Cancer. 1990;26:802-807.
87. Aas AT, Tonnessen TI, Brun A, et al. Growth inhibition of rat glioma cells in vitro and in vivo by aspirin. J Neurooncol. 1995;24:171-180.
88. Farrell CL, Megyesi J, Del Maestro RF. Effect of ibuprofen on tumor growth in the C6 spheroid implantation glioma model. J Neurosurg. 1998;68:925-930.
89. Arrieta O, Guevara P, Reyes S, et al. Paradoxical effect of aspirin on the growth of C6 rat glioma and on time of development of ENU-induced tumors of the nervous system. J Cancer Res Clin Oncol. 2001;127:681-686.
90. Giese A, Hagel C, Kim EL, et al. Thromboxane synthase regulates the migratory phenotype of human glioma cells. Neuro-oncol. 1999;1:3-13.
91. Kardosh A, Blumenthal M, Wang WJ, et al. Differential effects of selective COX-2 inhibitors on cell cycle regulation and proliferation of glioblastoma cell lines. Cancer Biol Ther. 2004 Jan [Epub ahead of print].
92. Sweeney CJ. Why cyclooxygenase-2 inhibition plus chemotherapy? Am J Clin Oncol. 2003;26:S122-S125.
93. Wagenaar-Miller RA, Hanley G, Shattuck-Brandt R, et al. Cooperative effects of matrix metalloproteinase and cyclooxygenase-2 inhibition on intestinal adenoma reduction. Br J Cancer. 2003;88:1445-1452.
94. Cassidy PB, Moos PJ, Kelly RC, et al. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin Cancer Res. 2002;8:846-855.
95. Moos PJ, Muskardin DT, Fitzpatrick FA. Effect of Taxol and Taxotere on gene expression in macrophages: induction of the prostaglandin H synthase-2 isoenzyme. J Immunol. 1999;162:467-473.
96. Subbaramaiah K, Hart JC, Norton L, et al. Microtubule-interfering agents stimulate the transcription of cyclooxygenase-2: evidence for involvement of ERK1/2 AND p38 mitogen-activated protein kinase pathways. J Biol Chem. 2000;275:14838-14845.
97. Munkarah AR, Genhai Z, Morris R, et al. Inhibition of paclitaxel-induced apoptosis by the specific COX-2 inhibitor, NS398, in epithetial ovarian cancer cells. Gynecol Oncol. 2003;88:429-433.
98. Becerra CR, Frenkel EP, Ashfaq R, et al. Increased toxicity and lack of efficacy of rofecoxib in combination with chemotherapy for treatment of metastatic colorectal cancer: a phase II study. Int J Cancer. 2003;105:868-872.
99. Langman MJ, Jensen DM, Watson DJ, et al. Adverse upper gastrointestinal effects of rofecoxib compared with NSAIDs. JAMA. 1999;282:1929-1933.
100. Roller A, Bähr OR, Streffer J, et al. Selective potentiation of drug cytotoxicity by NSAID in human glioma cells: the role of COX-1 and MRP. Biochem Biophys Res Commun. 1999;259:600-605.
101. Choy H, Milas L. Enhancing radiotherapy with cyclooxygenase-2 enzyme inhibitors: a rational advance? J Natl Cancer Inst. 2003; 95:1440-1452.
102. Milas L, Mason KA, Crane CH, et al. Improvement of radiotherapy or chemoradiotherapy by targeting COX-2 enzyme. Oncology (Hunting). 2003;17(5 suppl 5):15-24.
103. Milas L. Cyclooxygenase-2 (COX-2) enzyme inhibitors and radiotherapy: preclinical basis. Am J Clin Oncol. 2003;26(4 suppl 2): S66-S69.
104. Zaffroni N, Villa R, Orlandi L, et al. Differential effect of 9 beta-chloro-16,16-dimethyl prostaglandin E2 (nocloprost) on the radiation response of human normal fibroblasts and colon adenocarcinoma cells. Radiat Res. 1993;135:88-92.
105. Hanson WR, Thomas C. 16,16-dimethyl prostaglandin E2 increases survival of murine intestinal stem cells when given before photon radiation. Radiat Res. 1983;96:393-398.
106. Tomas-de la Vega JE, Banner BF, Hubbard M, et al. Cytoprotective effect of prostaglandin E2 in irradiated rat ileum. Surg Gynecol Obstet. 1984;158:39-45.
107. Milas L, Furuta Y, Hunter N, et al. Dependence of indomethacin-induced potentiation of murine tumor radioresponse on tumor host immunocompetence. Cancer Res. 1990;50:4473-4477.
108. Furuta Y, Hunter N, Barkley T Jr, et al. Increase in radioresponse of murine tumors by treatment with indomethacin. Cancer Res. 1988;48:3008-3013.
109. Furuta Y, Hall ER, Sanduja S, et al. Prostaglandin production by murine tumors as a predictor for therapeutic response to indomethacin. Cancer Res. 1988;48:3002-3007.
110. Palayoor ST, Bump EA, Calderwood SK, et al. Combined antitumor effect of radiation and ibuprofen in human prostate carcinoma cells. Clin Cancer Res. 1998;4:763-771.
111. Kishi K, Petersen S, Petersen C, et al. Preferential enhancement of tumor radioresponse by a cyclooxygenase-2 inhibitor. Cancer Res. 2000;60:1326-1331.
112. Milas L, Kishi K, Hunter N, et al. Enhancement of tumor response to gamma-radiation by an inhibitor of cyclooxygenase-2 enzyme. J Natl Cancer Inst. 1999;91:1501-1504.
113. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000; 60:1306-1311.
114. Nakata E, Mason KA, Hunter N, et al. Potentiation of tumor response to radiation or chemoradiation by selective cyclooxygenase-2 enzyme inhibitors. Int J Radiat Oncol Biol Phys. 2004;58: 369-375.
115. Petersen C, Petersen S, Milas L, et al. Enhancement of intrinsic tumor cell radiosensitivity induced by a selective cyclooxygenase-2 inhibitor. Clin Cancer Res. 2000;6:2513-2520
116. Raju U, Nakata E, Yang P, et al. In vitro enhancement of tumor cell radiosensitivity by a selective inhibitor of cyclooxygenase-2 enzymes: mechanistic considerations. Int J Radiat Oncol Biol Phys. 2002;54:886-894.
117. Dicker AP, Williams TL, Grant DS. Targeting angiogenic process by combination rofecoxib and ionizing radiation. Am J Clin Oncol. 2001;24:438-442.
118. Davis TW, Hunter N, Trifan OC, et al. COX-2 inhibitors as radiosensitizing agents for cancer therapy. Am J Clin Oncol. 2003;26(4 suppl 2)S58-S61.
119. Davis TW, O'Neal JM, Pagel MD, et al. Synergy between celecoxib and radiotherapy results from inhibition of cyclooxygenase-2 derived prostaglandin E2, a survival factor for tumor and associated vasculature. Cancer Res. 2004;64:279-285.